Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relenopride

Next Previous
Drug Profile

Relenopride

Alternative Names: SKL-IBS; YKP-10811; YKP-GI

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals
  • Developer SK biopharmaceuticals; SK Chemicals
  • Class Benzamides; Carbamates; Fluorobenzenes; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation; Irritable bowel syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO, Capsule)
  • 26 Jun 2015 Relenopride is still in phase-II development for Constipation in USA and South Korea
  • 01 Dec 2014 SK Chemicals completes a phase II trial in Irritable bowel syndrome and Constipation in South Korea (NCT02082457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top